AVBP
ArriVent BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.49
+3.61%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$13.43
From 52W high−61.17%
Volume1.60M
Market cap$665.16M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$13.43
From 52W high
−61.17%
Volume
1.60M
Market cap
$665.16M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
27.9
MomentumView details →
1D Return
+3.61%
YTD Return
−36.39%
SummaryUpdated Jun 1, 2026
ArriVent BioPharma, Inc. (NASDAQ:AVBP) is a clinical-stage biopharmaceutical company founded in 2021 and headquartered in Newtown Square, Pennsylvania. The company went public in January 2024 and focuses on developing targeted cancer therapies, particularly for non-small-cell lung cancer and other solid tumors. ArriVent operates in the highly specialized field of oncology drug development, with its lead asset being an advanced-stage cancer treatment currently in Phase 3 clinical trials.
Similar companies
Latest newsMore news →
ArriVent BioPharma, Inc. announced publication in Cell Press of results from the FURTHER Phase 1b study of firmonertinib in EGFR PACC-mutant non-small cell lung cancer.16d agoShanghai Allist Pharmaceuticals reported that its ArriVent equity stake had a carrying value of about 302 million yuan as of June 30, 2026, up 67.31% from the end of 2025.28d ago